Establishment of minimal positive-control conditions to ensure brain safety during rapid development of emergency vaccines.
10.4142/jvs.2017.18.S1.371
- Author:
Hyekyung BAEK
1
;
Kwang Ho KIM
;
Min Young PARK
;
Kyeongryun KIM
;
Bokyeong KO
;
Hyung Seok SEO
;
Byoung Soo KIM
;
Tae Wook HAHN
;
Sun Shin YI
Author Information
1. Department of Biomedical Laboratory Science, College of Medical Sciences, Soonchunhyang University, Asan 31538, Korea. admiral96@sch.ac.kr
- Publication Type:Original Article
- Keywords:
blood-brain barrier;
lipopolysaccharides;
positive-protocol;
tight junctions;
vaccine
- MeSH:
Animals;
Biomarkers;
Blood-Brain Barrier;
Brain*;
Clothing;
Emergencies*;
Hope;
Humans;
Lipopolysaccharides;
Mice;
Permeability;
Tight Junctions;
Vaccines*
- From:Journal of Veterinary Science
2017;18(S1):371-379
- CountryRepublic of Korea
- Language:English
-
Abstract:
With the increase in international human and material exchanges, contagious and infectious epidemics are occurring. One of the effective methods of epidemic inhibition is the rapid development and supply of vaccines. Considering the safety of the brain during vaccine development is very important. However, manuals for brain safety assays for new vaccines are not uniform or effective globally. Therefore, the aim of this study is to establish a positive-control protocol for an effective brain safety test to enhance rapid vaccine development. The blood-brain barrier's tight junctions provide selective defense of the brain; however, it is possible to destroy these important microstructures by administering lipopolysaccharides (LPSs), thereby artificially increasing the permeability of brain parenchyma. In this study, test conditions are established so that the degree of brain penetration or brain destruction of newly developed vaccines can be quantitatively identified. The most effective conditions were suggested by measuring time-dependent expressions of tight junction biomarkers (zonula occludens-1 [ZO-1] and occludin) in two types of mice (C57BL/6 and ICR) following exposure to two types of LPS (Salmonella and Escherichia). In the future, we hope that use of the developed positive-control protocol will help speed up the determination of brain safety of novel vaccines.
